Atglistatin is primarily used in research settings to inhibit adipose triglyceride lipase (ATGL), a key enzyme involved in the breakdown of stored fats in the body. By selectively blocking ATGL activity, Atglistatin helps scientists study lipid metabolism, energy homeostasis, and the role of lipolysis in various physiological and pathological conditions. It has been applied in studies related to obesity, insulin resistance, and fatty liver disease, where modulating fat breakdown can provide insights into disease mechanisms and potential therapeutic strategies. Additionally, Atglistatin is useful in exploring the link between lipid metabolism and inflammation or cardiovascular diseases, offering a tool to dissect the metabolic pathways involved without genetic manipulation.